EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

An Evaluation of First-in-Human Studies for RNA Oligonucleotides

Sydney Stern iD, Ronald L Wange, Hobart Rogers

Nucleic Acid Therapeutics · 2024

DOI: 10.1089/nat.2024.0036 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nucleic Acid Therapeutics, 2024. Verfasst von Sydney Stern und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, Office of Translational Science, Office of Clinical Pharmacology, US Food and Drug Administration, Silver Sp…. Hauptthemen laut MEDLINE: Oligonucleotides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most oligonucleotide therapeutics use Watson–Crick–Franklin base-pairing hybridization to target RNA and mitigate disease-related protein production. Using targets that were previously inaccessible to small molecules and biologics, synthetic nucleotides have provided treatments for severely debilitating and life-threatening diseases. However, these therapeutics possess unique pharmacologies that require specific considerations for their distribution, clearance, and other clinical pharmacology characteristics. Namely, one hurdle in the drug development of these therapeutics remains the prediction of human dose that results in exposures comparable with or below those seen at no observed adverse effect level in animals. For first-in-human (FIH) clinical trials, this often involves allometric scaling based on body surface area (BSA) or body weight (BW). In this study, we reviewed the current literature and surveyed elements across 16 approved oligonucleotide therapeutic New Drug Applications approved by the U.S. Food and Drug Administration in the period from September 1998 to January 2024, and 89 Investigational New Drug (IND) programs with available FIH clinical trials conducted from January 2015 to January 2024, to understand dose selection in early-stage development of oligonucleotide therapeutics. The surveyed elements across these programs include study design, route of administration, dosing regimen, interspecies scaling approach, and the most sensitive species. Of 89 IND programs and 16 approved therapeutics, intravenous and subcutaneous were the most common route of administration, no observable adverse event levels were frequently derived from nonhuman primates, BSA and BW were adjusted for in similar frequencies, patients were predominantly enrolled in FIH trials, and the most common design was a single or multiple ascending dose trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligonucleotidesHumansAnimalsRNAClinical Trials as TopicUnited StatesDrug ApprovalUnited States Food and Drug Administration

Stichwörter der Autor:innen

antisense oligonucleotidedrug developmentoligonucleotidesiRNA

Substanzen

OligonucleotidesRNA

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research, Office of Translational Science, Office of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Center for Drug Evaluation and Research, Office of the Medical Products and Tobacco (OMPT), Office of New Drug, US Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID-Profile: Sydney Stern

Förderung

  • Intramural FDA HHS

Zitieren

APA

Stern, S., Wange, R. L., & Rogers, H. (2024). An Evaluation of First-in-Human Studies for RNA Oligonucleotides. Nucleic Acid Therapeutics. https://doi.org/10.1089/nat.2024.0036

Vancouver

Stern S, Wange RL, Rogers H. An Evaluation of First-in-Human Studies for RNA Oligonucleotides. Nucleic Acid Therapeutics. 2024. doi:10.1089/nat.2024.0036

BibTeX
@article{Stern2024,
  author = {Stern, Sydney and Wange, Ronald L and Rogers, Hobart},
  title = {An Evaluation of First-in-Human Studies for RNA Oligonucleotides},
  journal = {Nucleic Acid Therapeutics},
  year = {2024},
  doi = {10.1089/nat.2024.0036}
}
Kostenlos starten →